Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Evotec, Sanofi Close Strategic Licensing Deal | Contract Pharma

What are you searching for?

Sign in
Breaking News

Evotec, Sanofi Close Strategic Licensing Deal

Evotec to accelerate infectious disease research pipeline and initiate new open innovation R&D initiatives

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Evotec AG has closed its strategic licensing transaction to integrate Sanofi’s infectious disease unit and research portfolio, resulting in a €60 million upfront cash payment and a financial commitment from Sanofi for five years.

Evotec will accelerate the infectious disease research pipeline development and initiate new open innovation R&D initiatives in anti-infectives. Going forward, Evotec will also engage in collaborations with other pharma and biopharma companies, academia and government agencies to further accelerate research and development into new products in infectious diseases. The initial focus areas will be on antimicrobial resistance (AMR) and superbug infections, TB and Malaria, as well as the creation of novel antiviral therapies with new mechanisms of action.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics